# ARA-290

> ARA-290, also studied under the name cibinetide, is a synthetic peptide designed to activate tissue-protective pathways associated with erythropoietin without stimulating red blood cell production. It has been investigated in clinical research for neuropathic pain, particularly in diabetic patients, and for its potential role in tissue repair and inflammation modulation. As a non-hematopoietic EPO analog, it is designed to engage the innate repair receptor while avoiding cardiovascular risks tied to traditional erythropoietin therapy. Clinical trials remain at a relatively early stage, and findings are considered preliminary.

- URL: https://www.lifeconverted.com/peptides/ara-290
- Also known as: Cibinetide
- Primary category: Healing & Recovery
- Effectiveness rank: #13 in Healing & Recovery
- Evidence level: Emerging research
- Route: Subcutaneous
- Dose range: 1,000-4,000 mcg
- Dose tiers: low 1000 mcg; moderate 2000 mcg; high 4000 mcg
- Half-life: Short half-life estimated at under 1 hour based on early pharmacokinetic research
- Timing: Morning
- Cycle: 4-8 weeks on, 4 weeks off (Cycling protocols are not well established given the early stage of clinical research.)
- Storage: Store lyophilized peptide frozen; reconstituted solution should be refrigerated and used within the supplier's recommended timeframe.

## Mechanism of action

ARA-290 is believed to bind the innate repair receptor, a complex distinct from the classical erythropoietin receptor involved in red blood cell production. Activation of this receptor is thought to trigger anti-inflammatory and cytoprotective signaling in damaged nerve and vascular tissue. This selective activity is proposed to allow tissue-protective effects without the erythropoietic side effects of standard EPO analogs.

## Reported benefits

- Studied for neuropathic pain reduction in diabetic patients
- Investigated for nerve fiber density support
- Explored for anti-inflammatory activity in vascular tissue
- Studied for potential wound healing support in diabetic complications
- Researched for tissue-protective effects without erythropoietic activity

## Reported side effects

- Injection site reaction
- Headache
- Mild flushing
- Limited long-term safety data from early-stage trials

## Common protocols

- 2000 mcg subcutaneous once daily in clinical trial settings for neuropathic pain research

---

Educational information only, not medical advice. Full disclaimer: https://www.lifeconverted.com/disclaimer